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Long interspersed nuclear element-1 (LINE-1 or L1) retrotransposons are insertional
mutagens capable of altering the genomic landscape in many ways. Activation of the
normally silent LINE-1 retrotransposon is associated with a high level of cancer-associated
DNA damage and genomic instability. Studies of LINE-1 have so far focused mainly on
changes in gene expression, and our knowledge of its impact on functional non-coding
RNAs is in its infancy. However, current evidence suggests that a signiﬁcant number
of human miRNAs originate from retrotransposon sequences. Furthermore, LINE-1 is
generally not expressed in normal tissues while its expression is widespread in epithelial
cancers. Based on our recent studies, we demonstrate a functional link between aberrant
LINE-1 expression and deregulation of let-7 miRNA expression. Since the expression of
let-7 is modulated by LINE-1 activity, we discuss possible mechanisms for this effect and
how the silencing of LINE-1 activation could provide new therapeutic options for cancer
treatment. Based on the deep sequencing of small RNAs in parallel with gene expression
proﬁling in breast cancer cells, we have identiﬁed potential pathways linking L1 activity to
let-7 processing and maturation and ultimately to the control of stemness in human cancer
cells.
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INTRODUCTION
Retrotransposons, a family of mobile genetic element, are themost
common repetitive elements in the human genome. Of these, the
long interspersed nuclear element-1 (LINE-1 or L1) and the Alu
elements are the most proliﬁc classes of retrotransposon, com-
prising 28% of the human genomic sequence. L1 is an insertional
mutagen capable of copying itself and reinserting into the genome
at multiple sites and is thereby capable of wreaking mutational
havoc on the genome. The activation of L1 retrotransposons and
ensuing L1 retrotransposition is also associated with a high fre-
quency of DNAbreaks and genomic instability (Symer et al., 2002)
and several studies have shown that there is a direct association
between the severity of cancer-associated DNA damage and the
activation of L1 expression (Belgnaoui et al., 2006; Wallace et al.,
2010). L1 also accelerates themobilization of Alu elements, certain
mRNAs and non-codingRNAs to new sites in the genome (Esnault
et al., 2000; Garcia-Perez et al., 2007), further altering cellular func-
tion in many ways. Because of these potentially harmful impacts
on genomic integrity, normal adult cells have developed a variety
of defense mechanisms, including epigenetic silencing, to prevent
the expression of L1 elements (Chen et al., 2012b; Rangasamy,
2013). Related to this, studies have shown that hypomethylation
of L1 promoters is associated with activation of L1 expression in
many types of cancer (Cruickshanks andTufarelli, 2009).When L1
elements become active, they can rapidly increase in copy number
by a “copy-and-paste”mechanism and become a source of genetic
mutations. For example, two recent studies have unveiled several
tumor-speciﬁcdenovoL1mutations in lung and liver cancers using
the transposable element analyzer (TEA) repeat analysis pipeline
and genome-wide mapping (Iskow et al., 2010; Lee et al., 2012).
A recent survey of whole genome sequences from a variety
of tumors included in the Cancer Genome Atlas (TCGA) project
also identiﬁed a number of L1-mediated insertional mutations
in colon, prostatic, colorectal, and ovarian cancers, suggest-
ing that L1-induced mutations are common in cancer cells and
tissues (Shukla et al., 2013). Despite these ﬁndings, questions
remain concerning whether the activation of L1 elements is
causative of cancer or merely occurs as an epiphenomenon due
to the unstable genomic state of cells. Although a clear con-
nection has been established between L1-induced mutations and
altered expression of affected genes, it is unclear if these repre-
sent cell-type-speciﬁc mutations or are sufﬁciently prevalent to
contribute to cancer pathology in general. The activation of L1
retrotransposons occurs mostly in cancers of epithelial origin.
In recent studies, we and others have shown that L1 expression
occurs in almost all the aggressive forms of human breast cancer
characterized by high rates of lymph node metastasis, includ-
ing estrogen-negative (ER-) tumors, which are characterized by
frequent distant metastasis and intrinsic resistance to hormone
therapy (Harris et al., 2010; Chen et al., 2012a). In support of these
ﬁndings, another study has shown that breast carcinomas release
retroviral-like particles into the extracellular space that contain
high levels of L1-encoded mRNA (Golan et al., 2008). Further-
more, the level of L1 elements is high in the plasma of patients
with breast cancer, melanoma, and lymphoma (Balaj et al., 2011),
suggesting a link between L1 activity and the recurrent forms of
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metastasis. Although the contribution of L1 activity to initiat-
ing the expression of certain protein-coding oncogenes such as
c-MET, typically via alternative promoters, has been recognized
(Cruickshanks and Tufarelli, 2009; Wolff et al., 2010), little is
known about the regulatory role of L1 elements (if any) for non-
coding RNA genes. A recent transcriptome study reports that an
L1 transcript driven by a viral HBV promoter, referred to as HBx-
LINE-1, does not encode a protein but produces a long non-coding
RNA (lncRNA) which induces the β-catenin signaling pathway
and facilitates the acquisition of a mesenchymal phenotype and
metastatic potential (Lau et al., 2014). Strikingly, HBx-LINE-1
expression has been found to occur in ∼25% of hepatocellular
carcinomas examined, and correlates with reduced patient sur-
vival. Although this ﬁnding suggests a role for L1 elements in
the development of liver cancer, it is not clear whether a similar
pattern of L1-driven lncRNA expression exists in other types of
cancer.
RETROTRANSPOSONS AS THE SOURCE OF NON-CODING
RNA
Growing evidence suggests a close association between the pres-
ence of retrotransposons in the intergenic regions of the human
genome and sources of non-coding RNAs, including miRNAs
and lncRNAs. Notably, ∼30% of human lncRNAs originate from
retrotransposons, in both sense and antisense orientations. In
addition, ∼80% of lncRNAs contain retrotransposon-derived
sequences embedded within or nearby their transcription start
sites, in which the retrotransposon sequences contribute signals
for lncRNA expression, splicing and processing (Kapusta et al.,
2013). Genome-wide analyses also reveal that lncRNAs are highly
enriched for LTR and HERV elements but are depleted of L1 and
Alu elements. Despite the low content of L1-derived sequences, a
recent study reported that a point mutation in an L1-containing
lncRNA sequence, which is located within an intron of SLC7A2,
leads to a defect in the expression of the lncRNA and results in a
lethal encephalopathy phenotype (Cartault et al., 2012). The pres-
ence of this L1 sequence is predicted to contribute to the proper
folding of the lncRNA, which is important for its function in the
brain.
Alu elements do not encode functional proteins for their
mobilization. Instead, Alu rely on the functioning of the L1
machinery. In fact, L1 elements are frequently found overlap-
ping Alu sequences at multiple locations in the genome and in
particular, in lncRNA sequences. Several recent studies suggest
that Alu elements present in lncRNAs can contribute to the reg-
ulatory role of these lncRNAs. One such Alu-mediated lncRNA
is APTR, which represses p21 expression by recruiting polycomb
repressive proteins to the p21 promoter. The presence of Alu
is crucial to the localization of APTR to the p21 promoter and
thus to regulation of cell growth and proliferation (Negishi et al.,
2014). Interestingly, this lncRNA also contains an L1 sequence
overlapping with closely spaced pairs of inverted Alu elements.
Whether the presence of the L1 sequence has any effects on the
functions of the lncRNA remains to be elucidated. The func-
tion of Alu elements is also linked to the expression of many
disease-related lncRNAs. As a key regulatory element, Alu medi-
ates the expression of an lncRNA, referred to as ANRIL (antisense
non-coding RNA in the INK4 locus), which binds to polycomb
group proteins and interacts with multiple target gene promot-
ers during the process of atherosclerosis (Holdt et al., 2013). The
presence of Alu in the lncRNA not only increases the expres-
sion of ANRIL transcripts but also marks the promoters of
target genes for epigenetic silencing. Strikingly, deletion or muta-
tion of the Alu sequence in ANRIL normalizes ANRIL-regulated
gene networks and cellular functions. These ﬁndings highlight a
new role for retrotransposons in epigenetic trans-regulation of
gene networks, which might be relevant to other lncRNAs as
well.
Another important layer of genetic control that shapes cellu-
lar functioning is the expression of microRNAs. Computational
studies reveal that miRNA target sites in the 3′-UTRs of genes can
be formed from embedded retrotransposon sequences, and also
that many miRNAs were initially formed from retrotransposon
sequences (Roberts et al., 2014). Most miRNAs are transcribed
as long primary transcripts (pri-miRNAs) and processed by
Drosha/Dicer to mature miRNAs with lengths of 20–22-nt. miR-
NAs regulate gene expression post-transcriptionally by binding
to one or more mRNAs, ultimately leading to the translational
inhibition or degradation of the target genes. Differential expres-
sion of miRNAs is observed in many types of cancer with some
of these miRNAs playing crucial roles in cancer onset and pro-
gression. There is also growing evidence that the seed sequences
of miRNAs are derived from retrotransposons (Borchert et al.,
2011). For instance, the miRNA-28 family originates from LINE
L2B elements. Several computational analyses have reported that
somemiRNAs share signiﬁcant sequence homology to retrotrans-
posons (Filshtein et al., 2012). In addition, a substantial number
of miRNAs contain hairpin sequences that are related to retro-
transposons. In further support of these ﬁndings, another recent
study has shown that several human miRNAs and miRNA target
sites in the 3′-UTRs of genes are, in fact, derived from L1, Alu, and
MIR elements (Spengler et al., 2014). Notably, ∼85% of miRNA
target sites overlap L1 and Alu elements, indicating that a strong
relationship exists between miRNA functionality and the activity
of retrotransposons.
Our group has recently shown that L1 elements are not
expressed in normal differentiated cells, but that their expres-
sion is widespread in all the types of breast tumors and breast
cancer cells examined so far, and correlates with poorer patient
survival (Chen et al., 2012a). Supplementary Table 1 summarizes
the expression of L1 elements determined by different investiga-
tors in a variety of cancer cells, tumor tissues, and animal-model
studies. To elucidate the molecular functions of L1 elements other
than those resulting in insertional mutations, we silenced the
expression of endogenous L1 elements in T47D breast cancer cells
using an L1-speciﬁc endo-siRNA that can speciﬁcally silence L1
expression through increased DNA methylation of L1 promoters
(Chen et al., 2012b). A genome-wide analysis of miRNA expres-
sionusing high-throughput deep sequencing showed strong global
upregulation of miRNA expression and very marked changes in
a number of speciﬁc miRNAs secondary to L1 silencing in this
cancer cell line (Ohms and Rangasamy, 2014). To our surprise,
most of the changes in miRNA expression occur mainly in the
let-7 family of miRNAs (Figure 1A). In particular, let-7a miRNA
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FIGURE 1 | (A) Long interspersed nuclear element-1 (L1) silencing
modulates the expression of the let-7 family of miRNAs. Barplot showing
DESeq-normalized absolute read counts for let-7 family miRNAs from
L1-silenced small RNA deep sequencing experiment in T47D breast cancer
cells. (B) Expression proﬁling of let-7a-target gene expression in T47D breast
cancer cells before and after silencing L1. Barplot showing normalized
absolute gene expression values for selected genes. Error bars show
mean ± SEM (n = 3 replicates for each experimental group).
was strongly upregulated from 149,428 normalized mapped reads
to 1,855,633 reads in L1 silenced cells, accounting for 40% of the
increase in the total normalized read counts in the L1-silenced
cells compared to cancer cells in which L1 remained active. This
massive increase in let-7a expression is intriguingly similar to the
differential expression of let-7a seen in normal cells and a vari-
ety of cancer cells in which the expression of let-7 is repressed
(Boyerinas et al., 2010).
Let-7a has a highly conserved sequence across organisms from
Caenorhabditis elegans to humans. It regulates the expression of
a range of genes through its 5′ seed sequence (5′-UGAGGUA-
3′), which binds to corresponding sequences located in the 3′
UTRs of genes. Let-7a is also known to target many onco-
genes including c-Myc, HMGA2, and Lin28, and its expression
is a hallmark of cell differentiation. Notably, the loss of let-7a
expression is often considered to have prognostic value since
it indicates poor survival in many cancers. Studies performed
in lung and renal cell carcinoma reveal that the overexpression
of let-7a inhibits in vitro cancer cell proliferation and in vivo
tumor regeneration by reducing the expression of c-Myc and
c-Myc targeted genes (Liu et al., 2012). Another major target of
let-7a is c-MET, which is one of the key genes activated by L1
expression in cancer cells (Wolff et al., 2010). Abnormal expres-
sion of c-MET induces multiple signal transduction pathways
involved in cancer growth and metastasis including the RAS,
PI3K, STAT3, and β-catenin pathways. For these reasons, there
is growing interest in the therapeutic use of let-7a itself, or phar-
macologicalmodulators of let-7a to treat human cancers in clinical
applications.
Expression of let-7a is subjected to complex regulation involv-
ing positive (p68/p72 helicases) and negative factors (c-Myc,
Lin28, hnRNPA1). The p68/p72 RNA helicases, as components
of the Drosha microprocessor complex, stimulate the process-
ing of pri-let-7 miRNAs into mature RNAs by Dicer-mediated
processing. The mature let-7a also binds to a complementary
region in the pri-let-7 miRNA, recruiting Argonaute and pro-
moting its own downregulation (Zisoulis et al., 2012). Moreover,
the expression of let-7a is also controlled by c-Myc binding to
the let-7 promoters which decreases its expression. c-Myc also
activates Lin28 expression by binding to the Lin28 promoters and
Lin28, in turn, binds selectively to pri-let-7 miRNAs and blocks
Dicer processing of pri-let-7 miRNAs into mature let-7a (Chang
et al., 2009). By repressing let-7a, Lin28 often acts as an onco-
gene in cancer cells (Viswanathan et al., 2009). Strikingly, Lin28 is
itself targeted by let-7a thus affecting the functioning of Lin28 in
a feedback circuit. Currently, however, few studies have addressed
the functional role of L1 in the expression of the let-7 miRNA
family. Thus, to clarify the role of L1, we carried out proﬁling
of let-7a-target gene expression, in breast cancer cells before and
after silencing L1. This study revealed that L1 silencing reduces
the expression of some let-7a-targeted genes including c-Myc and
c-MET, although only to a modest degree (Figure 1B). In another
study, inhibition of L1 activity by antiretroviral drugs was shown
to reduce c-Myc expression in cancer cells (Sciamanna et al., 2005),
which may partially explain the ability of L1-silencing to activate
let-7a. Importantly, our gene expression proﬁling shows that Dicer
is also signiﬁcantly upregulated in L1 silenced cells, which supports
a recent report of Dicer inhibiting L1 activation in human cells
(Heras et al., 2013). What is less clear from these studies is how L1
silencing leads to increased expression of let-7a miRNA in cancer
cells. Thus, the link between the let-7a miRNAs and the expression
of L1 elements in cancer cells requires further investigation.
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DOES L1 EXPRESSION INFLUENCE MIRNA EXPRESSION?
There is little or no direct evidence for a reciprocal relationship
between the silencing of L1 and let-7a expression in the literature.
Also, little is known about the relationship between the expression
of L1 elements and other miRNAs. So, how might L1 inﬂuence
the expression of the let-7a miRNA? One possible mechanism is
that retrotransposon sequences located in the promoter regions
of let-7 miRNAs might act as functional domains for their regu-
lation. Sequence analysis with the RepeatMasker database reveals
the presence of retrotransposon fragments scattered throughout
the promoter regions of the let-7 miRNAs, including L1, Alu,
and MIR elements. Given that the methylation status of the let-
7 promoters does not appear to play a signiﬁcant role in the
expression of let-7 miRNAs (Lu et al., 2007), it is conceivable
that these inserted retrotransposon transcripts interact with a
variety of host proteins, including RNA binding proteins, chro-
matin modiﬁers, and regulators of transcription/translation to
form an L1 ribonucleoprotein (RNP) complex. Notably, L1 and
Alu sequences have recently been shown to confer binding sites
for several chromatin regulatory complexes involving lncRNA
expression (Blackwell et al., 2012; Goodier et al., 2013). Regard-
less of whether the inserted retrotransposons within the promoter
regions of let-7 miRNAs are active or not, there are at least 100
copies of highly active L1 elements present in human cells (Brouha
et al., 2003). Several lines of evidence indicate that transcripts
from these L1 elements are associated with hnRNPA1, which is
an abundant RNA binding protein involved in splicing, process-
ing, and export of several pre-mRNAs to the cytoplasm (Goodier
et al., 2007; Sokolowski et al., 2013). Importantly, hnRNPA1 also
binds to pri-let-7a miRNAs and acts as a repressor of let-7 bio-
genesis by antagonizing the docking of KSRP (KH-type splicing
regulatory protein), which is a component of Drosha/Dicer com-
plexes and is known to positively regulate processing of miRNAs
(Michlewski and Caceres, 2010; Figure 2). Strikingly, except
for pre-let-7i, all the members of the let-7 family interact with
hnRNPA1. Thus, there is evidence of a relationship, at least in
the case of let-7a miRNAs, between the L1 activity and miRNA
expression.
An alternative but not mutually exclusive possibility is that
L1 silencing may activate miRNA-inducing proteins such as
transcription factors and RNA helicases that activate let-7 bio-
genesis. Intriguingly, our gene expression microarray proﬁling
of L1-silenced cells showed signiﬁcantly upregulated expression
of the DEAH box-containing DHX9 protein, which shares high
sequence similarity to the Drosophila maleless protein (MLE),
a protein that regulates dosage compensation (Kuroda et al.,
1991). DHX9 is an RNA helicase (also known as RNA heli-
case A, RHA, or NDHII) involved in the RNA-induced silencing
complex (RISC) assembly process (Fu and Yuan, 2013) as an
RISC-loading factor and this function is mediated by its dsRNA-
binding domains. Recently, DHX9 has been shown to interact
with Dicer, AGO2, and TRBP2 in miRNA loading and deple-
tion of DHX9 leads to reduced miRNA processing and RISC
assembly. Notably, DHX9 also interacts with the L1 RNP com-
plex, along with other RNA helicases, including MOV10, that can
potentially impede RISC function (Goodier et al., 2012). Strik-
ingly, a recent study proposed that Lin28 could antagonize the
FIGURE 2 | Schematic diagram of a model showing the role of L1 in
let-7 miRNA processing and maturation. L1 transcripts in human cancer
cells interact with hnRNPA1 to form an L1-hnRNPA1 complex. This complex
binds to pre-let-7 miRNA and prevents recruitment of KSRP regulatory
protein thus blocking the action of the microprocessor and preventing the
formation of mature let-7 miRNAs.
production of let-7a miRNAs by recruiting a DHX9-like RNA
helicase to promote its own translation (Kallen et al., 2012).
Together, these observations suggest that induction of DHX9
by L1 silencing (either directly or through interaction with
other proteins) can activate the expression of let-7a miRNAs.
However, further research is needed to evaluate the precise
function of L1 in the activation of the let-7 miRNAs. Given
that let-7 is often viewed as a tumor suppressor miRNA, a
strategy in which L1 activity is selectively inhibited pharmaco-
logically could provide new therapeutic options for human cancer
treatment.
In summary, this study has explored the relationship between
the expression of L1 elements and cancer onset and progression.
In this study we have shown, ﬁrst, that L1 activity is widespread in
epithelial cancers. Second, the expression of non-coding RNAs
including miRNAs and lncRNAs is closely associated with L1
activity. Third, we have demonstrated the interplay between the
aberrant expression of L1 elements and miRNAs, and in par-
ticular, the tumor suppressor miRNA let-7a. As we propose
above, there is a clear link between let-7a expression and the
silencing of L1 elements. Questions remain, however, as to how
L1 elements, either directly or in combination with other host
proteins contribute to the loss of let-7 expression in the vari-
ous types of cancer. Further studies are required to thoroughly
test the mechanisms proposed above by which L1 might affect
miRNA expression. Regardless of the answers to these questions,
the available data suggest that silencing of L1 expression holds
great therapeutic potential for the treatment of various epithelial
cancers.
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